keyword
MENU ▼
Read by QxMD icon Read
search

Ranibizumab

keyword
https://www.readbyqxmd.com/read/28630947/evolution-of-geographic-atrophy-in-participants-treated-with-ranibizumab-for-neovascular-age-related-macular-degeneration
#1
Alisa T Thavikulwat, Naima Jacobs-El, Jane S Kim, Elvira Agrón, Jesia Hasan, Catherine B Meyerle, David Valent, Catherine A Cukras, Henry E Wiley, Wai T Wong, Emily Y Chew
PURPOSE: To evaluate the risk factors, incidence, and rate of progression of geographic atrophy (GA) in eyes with neovascular age-related macular degeneration (nAMD) treated with ranibizumab. DESIGN: Post-hoc analysis of a prospective clinical study. PARTICIPANTS: 69 participants with nAMD in at least one eye. METHODS: Participants were prospectively treated in the study eye with 0.5 mg intravitreal ranibizumab. Study eyes received 4 monthly injections followed by pro re nata injections until a fluid-free macula was achieved on optical coherence tomography...
January 2017: Ophthalmology retina
https://www.readbyqxmd.com/read/28630787/evaluation-of-aflibercept-treatment-responses-in-eyes-with-bevacizumab-ranibizumab-resistant-wet-age-related-macular-degeneration
#2
Tuncay Topal, Taner Kar, Yıldıray Yıldırım, Sercan Koray Sağdıç, Cihan Büyükavşar, Abdullah Kaya, Ali Ayata, Murat Sönmez, Melih Hamdi Ünal
OBJECTIVES: To evaluate anatomic and functional results after switching from intravitreal bevacizumab or ranibizumab treatment to aflibercept for wet (neovascular) age-related macular degeneration. MATERIALS AND METHODS: This retrospective study included 22 eyes of 22 patients resistant to treatment with at least 6 injections of bevacizumab or ranibizumab. The first three injections had been applied monthly, the others pro re nata (PRN). Outcome measures were follow-up period, injection number, best corrected visual acuity (BCVA), central retinal thickness (CRT) and pigment epithelial detachment (PED) height...
June 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/28622326/clinical-real-world-results-of-switching-treatment-from-ranibizumab-to-aflibercept-in-patients-with-diabetic-macular-oedema
#3
V E Konidaris, K T Tsaousis, Z Al-Hubeshy, K Pieri, J Deane, T Empeslidis
No abstract text is available yet for this article.
June 16, 2017: Eye
https://www.readbyqxmd.com/read/28622321/identification-of-time-point-to-best-define-sub-optimal-response-following-intravitreal-ranibizumab-therapy-for-diabetic-macular-edema-based-on-real-life-data
#4
I Chatziralli, M Santarelli, N Patrao, L Nicholson, M Zola, R Rajendram, P Hykin, S Sivaprasad
PurposeTo determine the average time-point at which it is best to define 'sub-optimal response' after ranibizumab treatment for diabetic macular edema (DME) based on the data obtained from real-life clinical practice.MethodsIn this retrospective observational study, 322 consecutive treatment naïve eyes with DME were treated with three loading doses of intravitreal ranibizumab followed by re-treatment based on decision of the treating physician on a case-by-case basis. The demographic data, clinic-based visual acuity measurements and central subfield thickness (CST) assessed on spectral domain optical coherence tomography (OCT) were evaluated at baseline (month 0), 1, 2, 3, 6, and 12 months...
June 16, 2017: Eye
https://www.readbyqxmd.com/read/28620704/ranibizumab-versus-dexamethasone-implant-for-central-retinal-vein-occlusion-the-ranidex-study
#5
Irini Chatziralli, George Theodossiadis, Stamatina A Kabanarou, Efstratios Parikakis, Tina Xirou, Panagiotis Mitropoulos, Panagiotis Theodossiadis
PURPOSE: To compare intravitreal ranibizumab and dexamethasone implant in patients with macular edema (ME) secondary to central retinal vein occlusion (CRVO). METHODS: Participants were 42 treatment naive patients with ME due to CRVO, who received either intravitreal 0.5 mg ranibizumab (n = 25) or intravitreal 0.7 mg dexamethasone implant (n = 17). The main outcomes included the mean change in best corrected visual acuity (BCVA) and central subfield thickness (CST) at month 12 compared to baseline in the two groups...
June 15, 2017: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/28620652/visual-and-morphologic-outcomes-in-eyes-with-hard-exudate-in-the-comparison-of-age-related-macular-degeneration-treatments-trials
#6
Ebenezer Daniel, Juan E Grunwald, Benjamin J Kim, Maureen G Maguire, Glenn J Jaffe, Cynthia A Toth, Frederick L Ferris, Daniel F Martin, James Shaffer, Gui-Shuang Ying
PURPOSE: To compare baseline characteristics, visual acuity (VA) and morphological outcomes between eyes with baseline hard exudates (HE) and all other eyes among patients with neovascular age-related macular degeneration (NVAMD) treated with anti-vascular endothelial growth factors (anti-VEGF). DESIGN: Prospective cohort study within the Comparison of Age-Related Macular Degeneration Treatments Trials (CATT). PARTICIPANTS: Patients with NVAMD...
January 2017: Ophthalmology retina
https://www.readbyqxmd.com/read/28614133/time-course-of-changes-in-metamorphopsia-following-intravitreal-ranibizumab-injection-for-branch-retinal-vein-occlusion
#7
Yoshimi Sugiura, Fumiki Okamoto, Shohei Morikawa, Yoshifumi Okamoto, Takahiro Hiraoka, Tetsuro Oshika
PURPOSE: To evaluate the effects of intravitreal ranibizumab injection (IVR) on metamorphopsia in patients with branch retinal vein occlusion (BRVO) and to assess the relationship between retinal microstructure and metamorphopsia. METHODS: Subjects were 39 eyes of 39 patients with branch retinal vein occlusion. The severity of metamorphopsia was quantified using the M-CHARTS before and 1, 2, 3, 4, 5, and 6 months after treatment. Based on optical coherence tomography (OCT) images, we assessed central retinal thickness (CRT) and status of the external limiting membrane (ELM) and ellipsoid zone (EZ)...
June 13, 2017: Retina
https://www.readbyqxmd.com/read/28613352/comparison-of-ranibizumab-and-bevacizumab-for-macular-edema-secondary-to-retinal-vein-occlusions-in-routine-clinical-practice
#8
Mehnaz Khan, Karen M Wai, Fabiana Q Silva, Sunil Srivastava, Justis P Ehlers, Aleksandra Rachitskaya, Amy Babiuch, Ryan Deasy, Peter K Kaiser, Andrew P Schachat, Alex Yuan, Rishi P Singh
BACKGROUND AND OBJECTIVE: To determine outcomes of intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) versus bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA) for treatment of macular edema (ME) secondary to retinal vein occlusion (RVO) in routine clinical practice. PATIENTS AND METHODS: A retrospective study identified treatment-naïve patients with ME secondary to RVO where treatment with either IVB or IVR was initiated...
June 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28613221/clinicopathologic-correlation-of-retinal-angiomatous-proliferation-treated-with-ranibizumab
#9
Alison H Skalet, Audra K Miller, Michael L Klein, Andreas K Lauer, David J Wilson
PURPOSE: To describe histopathologic features of an eye with retinal angiomatous proliferation (RAP) secondary to age-related macular degeneration treated with serial ranibizumab injections and to correlate these findings with spectral domain optical coherence tomography. METHODS: Histopathologic features from serial sections through the globe of a 93-year-old man with age-related macular degeneration were studied and compared with spectral domain optical coherence tomography images obtained 7 weeks before his death...
April 26, 2017: Retina
https://www.readbyqxmd.com/read/28610573/correlation-between-short-and-long-term-effects-of-intravitreal-ranibizumab-therapy-on-macular-edema-after-branch-retinal-vein-occlusion-a-prospective-observational-study
#10
Yoshiro Minami, Taiji Nagaoka, Akihiro Ishibazawa, Akitoshi Yoshida
BACKGROUND: The correlation between the short- and long-term effects of intravitreal ranibizumab (IVR) on macular edema after branch retinal vein occlusion (BRVO) remains unclear. We assessed the correlation between the short- and long-term effects of IVR on macular edema after BRVO. METHODS: Twenty-one eyes with macular edema after BRVO were enrolled in this prospective observational study. We measured the foveal thickness (FT) and the best-corrected visual acuity (BCVA) before, 1 day after, and 1 month after IVR (0...
June 13, 2017: BMC Ophthalmology
https://www.readbyqxmd.com/read/28606479/therapeutic-potential-of-ranibizumab-in-corneal-neovascularization
#11
Marianne L Shahsuvaryan
Ranibizumab is a humanized, affinity-matured vascular endothelial growth factor (VEGF) antibody fragment that neutralizes all isoforms of VEGF and is FDA approved for use in ophthalmology. Recently it was suggested that ranibizumab may be useful in the treatment of corneal neovascularization, but in reality this therapy is not yet evidence based.
June 9, 2017: Trends in Pharmacological Sciences
https://www.readbyqxmd.com/read/28604541/high-dose-high-frequency-aflibercept-for-recalcitrant-neovascular-age-related-macular-degeneration
#12
Qi Sheng You, Raouf Gaber, Amit Meshi, Hema L Ramkumar, Mostafa Alam, Ilkay Kilic Muftuoglu, William R Freeman
PURPOSE: To determine the efficacy of monthly (0.1 mL/4 mg) aflibercept for refractory neovascular age-related macular degeneration (wet age-related macular degeneration). METHODS: This was a retrospective interventional case series in which patients with wet age-related macular degeneration were treated with stepwise dose escalation. Nonvitrectomized patients resistant to monthly (Q4W) ranibizumab/bevacizumab were switched to 2 mg aflibercept every 8 weeks. With resistance, they were escalated to Q4W 2 mg aflibercept, then Q4W 4 mg (high dose high frequency, 4Q4W) aflibercept...
June 9, 2017: Retina
https://www.readbyqxmd.com/read/28601887/comparative-retinal-vessel-size-study-of-intravitreal-ranibizumab-and-bevacizumab-in-eyes-with-neovascular-age-related-macular-degeneration
#13
Muhammed Mustafa Kurt, Osman Çekiç, Çetin Akpolat, Murat Aslankurt, Mustafa Nuri Elçioğlu
PURPOSE: The aim of this paper was to assess and compare the effects of intravitreal ranibizumab and bevacizumab on retinal vessel diameter in eyes with neovascular age-related macular degeneration (AMD). METHODS: Patients with neovascular AMD who underwent intravitreal injection of either ranibizumab or bevacizumab were included. Noninjected fellow eyes served as a control. The main outcome measures were central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and the artery-vein ratio (AVR)...
June 10, 2017: Ophthalmologica. Journal International D'ophtalmologie
https://www.readbyqxmd.com/read/28596286/one-year-outcome-of-intravitreal-ziv-aflibercept-therapy-for-non-responsive-neovascular-age-related-macular-degeneration
#14
Imoro Zeba Braimah, Komal Agarwal, Ahmad Mansour, Jay Chhablani
AIM: To evaluate 12-month outcome of intravitreal ziv-aflibercept (IVZ) therapy in eyes with neovascular age-related macular degeneration (nAMD) that are non-responsive to bevacizumab and ranibizumab. METHODS: This retrospective study included 16 eyes (14 patients) with nAMD who were on prior treatment with bevacizumab and ranibizumab and were treated with as-needed IVZ (1.25 mg/0.05 mL) for 12 months. The primary outcome measure was the mean change in best corrected visual acuity (BCVA) and secondary outcome measures included mean change in central macular thickness (CMT), retinal pigment epithelial detachment (RPED) heights, longest treatment free interval, presence of subretinal fluid (SRF) and intraretinal fluid (IRF) and adverse events...
June 8, 2017: British Journal of Ophthalmology
https://www.readbyqxmd.com/read/28592811/evaluating-the-impact-of-vitreomacular-adhesion-on-anti-vegf-therapy-for-retinal-vein-occlusion-using-machine-learning
#15
Sebastian M Waldstein, Alessio Montuoro, Dominika Podkowinski, Ana-Maria Philip, Bianca S Gerendas, Hrvoje Bogunovic, Ursula Schmidt-Erfurth
Vitreomacular adhesion (VMA) represents a prognostic biomarker in the management of exudative macular disease using anti-vascular endothelial growth factor (VEGF) agents. However, manual evaluation of VMA in 3D optical coherence tomography (OCT) is laborious and data on its impact on therapy of retinal vein occlusion (RVO) are limited. The aim of this study was to (1) develop a fully automated segmentation algorithm for the posterior vitreous boundary and (2) to study the effect of VMA on anti-VEGF therapy for RVO...
June 7, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28590318/five-year-outcomes-of-intravitreal-injection-of-ranibizumab-for-the-treatment-of-myopic-choroidal-neovascularization
#16
Tsung-Tien Wu, Ya-Hsin Kung
PURPOSE: To evaluate the 5-year outcomes, efficacy, and safety of intravitreal ranibizumab injections for the treatment of myopic choroidal neovascularization. METHODS: The medical records of 18 consecutive eyes of 14 patients who received intravitreal injections of ranibizumab for myopic choroidal neovascularization with a follow-up of 5 years were retrospectively reviewed. Outcomes included best-corrected visual acuity, total number of treatments, and complications...
January 11, 2017: Retina
https://www.readbyqxmd.com/read/28587414/effect-of-intravitreal-injection-of-ranibizumab-on-retinal-ganglion-cells-and-microvessels-in-the-early-stage-of-diabetic-retinopathy-in-rats-with-streptozotocin-induced-diabetes
#17
Ang Xiao, Qiong Zhou, Yi Shao, Hui-Feng Zhong
The aim of the present study was to investigate the effect of intravitreal injection of ranibizumab on retinal ganglion cells and microvessels at the early stage of diabetic retinopathy (DR) in rats with streptozotocin-induced diabetes mellitus (DM). DM was induced by a single intraperitoneal injection of 60 mg/kg body weight streptozotocin. A total of 80 diabetic rats were randomly assigned to four treatment groups (n=20 in each group) and were treated with an oculus dexter intravitreal injection of ranibizumab...
June 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28584672/keratoacanthoma-of-the-nasal-septum-secondary-to-ranibizumab-use
#18
Jason E Cohn, Hilary M Caruso Sales, Giang Huong Nguyen, Harvey Spector, Kenneth Briskin
Keratoacanthoma (KA) is a benign epithelial tumor that typically presents as a firm, cone-shaped, flesh-colored nodule with a central horn-filled crater. KA is considered to be a low-grade variant of squamous cell carcinoma (SCC). We report a rare case of a 72-year-old male who presented with a KA involving the nasal septum, possibly related to ranibizumab use. A flesh-colored lesion on the right anterior nasal septum lesion was visualized on examination. Histologic examination revealed a well-circumscribed, dome-shaped central crater filled with keratin, well-differentiated squamous epithelium with ground-glass cytoplasm with pushing margins, and intraepithelial microabscesses establishing the diagnosis of KA...
2017: Case Reports in Pathology
https://www.readbyqxmd.com/read/28576208/long-term-in-vitro-functional-stability-of-compounded-ranibizumab-and-aflibercept
#19
Sijia Cao, Jing Cui, Joanne Matsubara, Farzin Forooghian
OBJECTIVE: To determine the long-term in vitro functional stability of compounded ranibizumab and aflibercept. DESIGN: Laboratory study. METHODS: Ranibizumab and aflibercept were compounded into plastic syringes and stored under refrigerated conditions for up to 4 weeks. Half maximal inhibitory concentrations (IC50) from dose-response curves generated by using drugs and their respective targets in enzyme-linked immunosorbent assays were calculated...
June 2017: Canadian Journal of Ophthalmology. Journal Canadien D'ophtalmologie
https://www.readbyqxmd.com/read/28575913/-results-of-re-switch-from-intravitreal-aflibercept-to-ranibizumab-in-patients-with-exudative-age-related-macular-degeneration
#20
Sören Waibel, Egbert Matthé, Dirk Sandner
Background The purpose of this study was to investigate the effectiveness of re-switch from intravitreal aflibercept to ranibizumab in patients with exudative age-related macular degeneration. Materials and Methods This retrospective case series included 17 eyes of 17 patients who had previously switched from ranibizumab to aflibercept and finally back to ranibizumab. Main outcomes were change of visual acuity (VA) and assessment of central macular thickness (CMT). Secondary outcomes included predictive factors which had a beneficial effect as VA and CMT before re-switch, number of previous injections and gender...
June 2, 2017: Klinische Monatsblätter Für Augenheilkunde
keyword
keyword
1767
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"